Literature DB >> 9355134

Attention and clinical symptoms in schizophrenia.

B Cornblatt1, M Obuchowski, D B Schnur, J D O'Brien.   

Abstract

Attentional deficits, long established to characterize patients with schizophrenia spectrum disorders, have traditionally been regarded as part of the disorder's clinical syndrome. In this paper we provide evidence to indicate that: a) impaired attention is a dimension of schizophrenia that is independent of clinical state, and b) that attention does not appear to respond to the medication (i.e. standard neuroleptics) most typically used to treat clinical symptoms. Since intact attention and other cognitive processes appear critical to successful functioning in the community after hospital discharge, these findings have major implications for treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355134     DOI: 10.1023/a:1025495030997

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  39 in total

1.  Signal detection indices in schizophrenics on a visual, auditory, and bimodal Continuous Performance Test.

Authors:  L Mussgay; R Hertwig
Journal:  Schizophr Res       Date:  1990 Oct-Dec       Impact factor: 4.939

2.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

3.  The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families.

Authors:  B A Cornblatt; N J Risch; G Faris; D Friedman; L Erlenmeyer-Kimling
Journal:  Psychiatry Res       Date:  1988-11       Impact factor: 3.222

4.  Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity.

Authors:  B A Cornblatt; L Erlenmeyer-Kimling
Journal:  J Abnorm Psychol       Date:  1985-11

5.  Attention dysfunction in chronic schizophrenia.

Authors:  M H Orzack; C Kornetsky
Journal:  Arch Gen Psychiatry       Date:  1966-03

Review 6.  A neurodevelopmental approach to the classification of schizophrenia.

Authors:  R M Murray; E O'Callaghan; D J Castle; S W Lewis
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

7.  Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance.

Authors:  E A Earle-Boyer; M R Serper; M Davidson; P D Harvey
Journal:  Psychiatry Res       Date:  1991-04       Impact factor: 3.222

8.  Relations between attentional deficits and clinical symptoms in schizophrenic outpatients.

Authors:  M E Strauss; R W Buchanan; J Hale
Journal:  Psychiatry Res       Date:  1993-06       Impact factor: 3.222

9.  Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

Authors:  A J Saykin; D L Shtasel; R E Gur; D B Kester; L H Mozley; P Stafiniak; R C Gur
Journal:  Arch Gen Psychiatry       Date:  1994-02

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  17 in total

1.  Beneficial effects of electrostimulation contingencies on sustained attention and electrocortical activity.

Authors:  Max Jean-Lon Chen; Trevor Thompson; Juri Kropotov; John H Gruzelier
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

2.  White matter abnormalities and cognitive impairment in early-onset schizophrenia-spectrum disorders.

Authors:  Katherine A Epstein; Kathryn R Cullen; Bryon A Mueller; Paul Robinson; Susanne Lee; Sanjiv Kumra
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-12-25       Impact factor: 8.829

Review 3.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

4.  Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the at-risk mental states for psychosis.

Authors:  Nikolaos Koutsouleris; Christian Gaser; Katja Patschurek-Kliche; Johanna Scheuerecker; Ronald Bottlender; Petra Decker; Gisela Schmitt; Maximilian Reiser; Hans-Jürgen Möller; Eva M Meisenzahl
Journal:  Hum Brain Mapp       Date:  2011-08-30       Impact factor: 5.038

5.  Parvalbumin-containing GABA cells and schizophrenia: experimental model based on targeted gene delivery through adeno-associated viruses.

Authors:  Marta U Woloszynowska-Fraser; Peer Wulff; Gernot Riedel
Journal:  Behav Pharmacol       Date:  2017-12       Impact factor: 2.293

Review 6.  Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis.

Authors:  Warrick J Brewer; Stephen J Wood; Lisa J Phillips; Shona M Francey; Christos Pantelis; Alison R Yung; Barbara Cornblatt; Patrick D McGorry
Journal:  Schizophr Bull       Date:  2006-06-16       Impact factor: 9.306

7.  Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia.

Authors:  Christoph U Correll; Christopher W Smith; Andrea M Auther; Danielle McLaughlin; Manoj Shah; Carmel Foley; Ruth Olsen; Todd Lencz; John M Kane; Barbara A Cornblatt
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

8.  Psychosis risk screening in clinical high-risk adolescents: a longitudinal investigation using the Child Behavior Checklist.

Authors:  Diana I Simeonova; Theresa Nguyen; Elaine F Walker
Journal:  Schizophr Res       Date:  2014-08-27       Impact factor: 4.939

Review 9.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

10.  White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia.

Authors:  Thomas Zetzsche; Ulrich W Preuss; Thomas Frodl; Gerda Leinsinger; Christine Born; Maximilian Reiser; Ulrich Hegerl; Hans-Jürgen Möller; Eva M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04-24       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.